CAM-101 is under clinical development by Cambium Bio and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CAM-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAM-101 overview
CAM-101 (Elate ocular) is under development for the treatment of keratoconjunctivitis sicca (dry eye) secondary to graft versus host disease. It is administered through ophthalmic route in the form of drops. The drug candidate is a fibrinogen depleted human platelet lysate (FD-HPL) based product being developed based on Aurarix FD-HPL platform technology.
Cambium Bio overview
Cambium Bio, formerly Regeneus, develops cell-based therapies for neuropathic pain, osteoarthritis and skin conditions. It is investigating the Progenza technology platform which utilizes secretome to develop therapies that improve mesenchymal signaling cells (MSCs) and treat knee osteoarthritis and neuropathic pain. The company is also evaluating the Sygenus platform, a cell-free topical serum and gel treatment for age spots and acne, wound healing and vulva lichen planus. It’s research and development partners include Kyocera Corp, Monash University, The University of Adelaide, the University of New South Wales and the Agency for Science, Technology and Research (A*STAR). Cambium Bio is headquartered in Sydney, New South Wales, Australia.
For a complete picture of CAM-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
